Therapeutic potential and formulation considerations of orally disintegrating films in acute disorders

The pharmaceutical industry is a persistently growing industry, with numerous innovations taking place to improve patient compliance and reduce the disadvantages of traditional formulations. One of these innovations is orally disintegrating films (ODFs), which are thin polymer films that quickly dissolve upon contact with saliva. ODFs can be beneficial where conventional dosage forms, such as capsules, tablets, and granules, present difficulties for certain patients, including pediatric, geriatric, and unconscious patients who may have trouble swallowing. Different types of polymers help the Active Pharmaceutical Ingredient (API) by influencing its solubility profile, improving disintegration, taste masking bitter drugs, and increasing overall stability. Additionally, ODFs eliminate the need for water and dissolve instantly in the oral cavity, offering improved convenience for patients. All these properties make ODFs ideal for managing acute conditions like pain, fever, nausea, or allergic reactions, where a rapid onset of action is required. By optimizing different types of polymers and additives, manufacturers can ensure precise dosing, quick drug absorption through the oral cavity, bypassing the gastrointestinal tract, and minimizing first-pass metabolism.